# Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia

> **NCT00270049** · PHASE2 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 195 (actual)

## Conditions studied

- Anemia
- Leukemia, Lymphocytic, Chronic
- Leukemia, Lymphocytic
- Cancer
- Neoplasms
- Quality of Life

## Interventions

- **DRUG:** epoetin alfa

## Key facts

- **NCT ID:** NCT00270049
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1990-11
- **Primary completion:** —
- **Final completion:** 1994-01
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2011-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00270049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00270049, "Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00270049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*